AZUR-4 Phase II trial tests neoadjuvant dostarlimab plus CAPEOX in MSS stage III colon cancer

◆ TRIAL DATA

This randomized Phase II study compares neoadjuvant dostarlimab plus CAPEOX versus CAPEOX alone in previously untreated T4N0 or stage III mismatch repair proficient/microsatellite stable resectable colon cancer. (Clinical Colorectal Cancer)